Compile Data Set for Download or QSAR
Report error Found 46 Enz. Inhib. hit(s) with all data for entry = 50043123
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436391(CHEMBL2396865)
Affinity DataIC50: 1nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436376(CHEMBL2396842)
Affinity DataIC50: 2nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436393(CHEMBL2396863)
Affinity DataIC50: 4nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436382(CHEMBL2396836)
Affinity DataIC50: 5nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436389(CHEMBL2396867)
Affinity DataIC50: 7nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436379(CHEMBL2396839)
Affinity DataIC50: 7nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436383(CHEMBL2396835)
Affinity DataIC50: 8nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50292929(almorexant | CHEMBL455136)
Affinity DataIC50: 8nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436380(CHEMBL2396838)
Affinity DataIC50: 9nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50431845(CHEMBL2347607)
Affinity DataIC50: 9nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50431860(CHEMBL2347482)
Affinity DataIC50: 9nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436394(CHEMBL2396862)
Affinity DataIC50: 9nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436395(CHEMBL2396861)
Affinity DataIC50: 10nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436378(CHEMBL2396840)
Affinity DataIC50: 10nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436386(CHEMBL2396870)
Affinity DataIC50: 12nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50292929(almorexant | CHEMBL455136)
Affinity DataIC50: 13nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436385(CHEMBL2396833)
Affinity DataIC50: 14nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436380(CHEMBL2396838)
Affinity DataIC50: 16nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436383(CHEMBL2396835)
Affinity DataIC50: 16nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436392(CHEMBL2396864)
Affinity DataIC50: 16nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436381(CHEMBL2396837)
Affinity DataIC50: 16nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436385(CHEMBL2396833)
Affinity DataIC50: 17nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436384(CHEMBL2396834)
Affinity DataIC50: 17nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436390(CHEMBL2396866)
Affinity DataIC50: 18nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436387(CHEMBL2396869)
Affinity DataIC50: 18nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436389(CHEMBL2396867)
Affinity DataIC50: 18nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436387(CHEMBL2396869)
Affinity DataIC50: 20nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436377(CHEMBL2396841)
Affinity DataIC50: 26nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50431845(CHEMBL2347607)
Affinity DataIC50: 30nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436382(CHEMBL2396836)
Affinity DataIC50: 30nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436384(CHEMBL2396834)
Affinity DataIC50: 32nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50431860(CHEMBL2347482)
Affinity DataIC50: 40nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436386(CHEMBL2396870)
Affinity DataIC50: 45nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436378(CHEMBL2396840)
Affinity DataIC50: 53nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436395(CHEMBL2396861)
Affinity DataIC50: 72nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436391(CHEMBL2396865)
Affinity DataIC50: 74nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436379(CHEMBL2396839)
Affinity DataIC50: 91nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436377(CHEMBL2396841)
Affinity DataIC50: 94nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436376(CHEMBL2396842)
Affinity DataIC50: 170nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436390(CHEMBL2396866)
Affinity DataIC50: 203nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436388(CHEMBL2396868)
Affinity DataIC50: 227nMAssay Description:Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436393(CHEMBL2396863)
Affinity DataIC50: 312nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436381(CHEMBL2396837)
Affinity DataIC50: 378nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436394(CHEMBL2396862)
Affinity DataIC50: 431nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436388(CHEMBL2396868)
Affinity DataIC50: 547nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50436392(CHEMBL2396864)
Affinity DataIC50: 3.90E+3nMAssay Description:Antagonist activity at human OX1R expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed